Gaurav Aggarwal

Managing Partner
​Vivo Capital, LLC

​​​​
​

Dr. Aggarwal has been an investor in the life sciences sector for more than twenty years. He rejoined Vivo as a Managing Partner in April 2024 after being a Managing Director from 2016 to 2023 and Chief Investment Officer of our U.S. public investment fund from 2021 to 2023. Dr. Aggarwal previously served as the Chief Business Officer of Ocera Therapeutics, Inc., a publicly traded clinical stage company developing therapies for orphan liver conditions, from April 2014 through October 2016; as Managing Director of Investor Growth Capital from January 2013 through December 2013; and as a General Partner at Panorama Capital, L.P., a venture capital fund, from August 2006 through December 2012. Earlier in his career, Dr. Aggarwal was an associate with JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co.

Dr. Aggarwal has served on the boards of Unicycive Therapeutics and Geron since March and November 2023, respectively. He previously held positions on the boards of Sierra Oncology, Inc. (acquired by GlaxoSmithKline plc), Hyperion Therapeutics, Inc. (acquired by Horizon Pharma plc), and on several privately held biopharmaceutical companies.

Dr. Aggarwal received his M.D. from Columbia University, College of Physicians & Surgeons, and his B.S. in Agricultural Economics from Cornell University.

Speech title & Synopsis

​
Panel Discussion- Innovative Investment Strategies for New Drug Development
 

Panelist